Cancer

Article	Citations
The ever‐increasing importance of cancer as a leading cause of premature death worldwide	931
Breast cancer early detection: A phased approach to implementation	260
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy	260
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial	195
Mammography screening reduces rates of advanced and fatal breast cancers: Results in 549,091 women	170
Annual report to the nation on the status of cancer, part 1: National cancer statistics	141
Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system	133
The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types	114
Second cancer risk after primary cancer treatment with three‐dimensional conformal, intensity‐modulated, or proton beam radiation therapy	102
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma	102
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases	101
Novel HER2–targeted therapies for HER2–positive metastatic breast cancer	98
Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities	97
Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study	87
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179	85
Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta‐analysis of cohort studies	85
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study	83
De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017	80
Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospectiv	78
Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax	77
The impact of COVID‐19 on the cancer care of adolescents and young adults and their well‐being: Results from an online survey conducted in the early stages of the pandemic	75
Breast cancer treatment: A phased approach to implementation	74
Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years	72
Outcomes of novel coronavirus disease 2019 (COVID‐19) infection in 107 patients with cancer from Wuhan, China	72
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach	71

Pediatric cancer mortality and survival in the United States, 2001‐2016	69
Impact of the COVID‐19 pandemic on diagnosis of new cancers: A national multicenter study of the Veterans Affairs Healthcare System	68
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials	67
Perioperative COX2 and β‐adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial	64
Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis	63
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID‐19	60
The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global	60
Osteosarcoma: A Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017	59
Population‐level impact of coronavirus disease 2019 on breast cancer screening and diagnostic procedures	58
Management of primary skin cancer during a pandemic: Multidisciplinary recommendations	58
Impact of the coronavirus disease 2019 (COVID‐19) pandemic on pediatric oncology care in the Middle East, North Africa, and West Asia region: A report from the Pediatric Oncology East and Mediterranea	57
Low‐dose whole‐lung radiation for COVID‐19 pneumonia: Planned day 7 interim analysis of a registered clinical trial	57
Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial	55
Oral infectious bacteria in dental plaque and saliva as risk factors in patients with esophageal cancer	54
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies	50
The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource‐Stratified Phased Implementation: Methods and overview	49
Emerging cancer incidence trends in Canada: The growing burden of young adult cancers	47
Multivariate mortality analyses in COVID‐19: Comparing patients with cancer and patients without cancer in Louisiana	47
Impact of the COVID‐19 pandemic on a population‐based breast cancer screening program	47
A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort	47
Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women’s Health Initiative	46
Age distributions of breast cancer diagnosis and mortality by race and ethnicity in US women	46
Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial	46
Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16INK4a and frailty	46
Loneliness and mental health during the COVID‐19 pandemic in older breast cancer survivors and noncancer controls	45
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma	45
COVID‐19 outcomes of patients with gynecologic cancer in New York City	45
Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study	45
Breast cancer treatment delays by socioeconomic and health care access latent classes in Black and White women	45
Potential impact of family history–based screening guidelines on the detection of early‐onset colorectal cancer	44
Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma	44
The future of cancer screening after COVID‐19 may be at home	44
Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group	43
The role of dissemination and implementation science in global breast cancer control programs: Frameworks, methods, and examples	43
What matters most: Randomized controlled trial of breast cancer surgery conversation aids across socioeconomic strata	42
Timing, number, and type of sexual partners associated with risk of oropharyngeal cancer	42
Breast imaging, breast surgery, and cancer genetics in the age of COVID‐19	41
Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses	41
Desmoid tumors: To treat or not to treat, That is the question	41
Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy	40
First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid	40
Head and neck cancer surgery during the COVID‐19 pandemic: An international, multicenter, observational cohort study	40
Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors	40
A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia	39
Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies	39
Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non–small cell lung cancer	38
Health‐related quality of life outcomes among breast cancer survivors	38
Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer	38
A combination of enhanced recovery after surgery and prehabilitation pathways improves perioperative outcomes and costs for robotic radical prostatectomy	38
NPC‐0501 trial on the value of changing chemoradiotherapy sequence, replacing 5‐fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma	37

Associations between artificial light at night and risk for thyroid cancer: A large US cohort study	37
Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy	37
Extrameningeal solitary fibrous tumors—surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarco	37
High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean	37
Moving through cancer: Setting the agenda to make exercise standard in oncology practice	37
Economic distress, financial toxicity, and medical cost‐coping in young adult cancer survivors during the COVID‐19 pandemic: Findings from an online sample	37
Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case‐control study	37
Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis	37
Loneliness and symptom burden in oncology patients during the COVID‐19 pandemic	36
Bereaved parents' views on end‐of‐life care for children with cancer: Quality marker implications	36
Mammographic breast density, its changes, and breast cancer risk in premenopausal and postmenopausal women	36
Cancer attributable to human papillomavirus infection in China: Burden and trends	36
Cell‐free human papillomavirus DNA kinetics after surgery for human papillomavirus–associated oropharyngeal cancer	35
Clinical characteristics, medical service utilization, and expenditure for colorectal cancer in China, 2005 to 2014: Overall design and results from a multicenter retrospective epidemiologic survey	35
Etoposide and cisplatin versus irinotecan and cisplatin as the first‐line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase	35
The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms	35
What is empathy? Oncology patient perspectives on empathic clinician behaviors	35
Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer	34
Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID‐19 pandemic: The Princess Margaret experience and proposal	34
JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer	34
Fiber consumption and breast cancer incidence: A systematic review and meta‐analysis of prospective studies	34
A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia	34
Trajectories of fear of cancer recurrence in young breast cancer survivors	33
Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety	33
Social determinants of health and cancer mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study	33
Effects of a mindfulness‐based intervention on cancer‐related cognitive impairment: Results of a randomized controlled functional magnetic resonance imaging pilot study	33
Racial disparities in Black men with prostate cancer: A literature review	32
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia	32
Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibit	32
Symptom clusters in 1330 survivors of 7 cancer types from the PROFILES registry: A network analysis	32
Long‐term survival among 5‐year survivors of adolescent and young adult cancer	32
Cancer patients' experiences with medicinal cannabis–related care	32
Changes in breast cancer screening rates among 32 community health centers during the COVID‐19 pandemic	31
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)	31
Cancer pain self‐management in the context of a national opioid epidemic: Experiences of patients with advanced cancer using opioids	31
Global, regional, and national burden of lung cancer and its attributable risk factors, 1990 to 2017	31
Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy	31
Obesity, race, and long‐term prostate cancer outcomes	31
Pain in long‐term survivors of childhood cancer: A systematic review of the current state of knowledge and a call to action from the Children's Oncology Group	31
Importance of quality‐of‐life priorities and preferences surrounding treatment decision making in patients with cancer and oncology clinicians	31
Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin	30
Defining the role of neoadjuvant systemic therapy in high‐risk retroperitoneal sarcoma: A multi‐institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group	30
Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer	30
Do all patients with cancer experience fatigue? A longitudinal study of fatigue trajectories in women with breast cancer	30
Strategies to improve diversity, equity, and inclusion in clinical trials	29
The METeoric rise of MET in lung cancer	29
Oral microbiome and onset of oral mucositis in patients with squamous cell carcinoma of the head and neck	29
What 20 years of research has taught us about the TP53 p.R337H mutation	29
Determinants of quality of life in patients with incurable cancer	29
Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis	29
Material and psychological financial hardship related to employment disruption among female adolescent and young adult cancer survivors	29
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia	29
Lung cancer screening eligibility and use with low‐dose computed tomography: Results from the 2018 Behavioral Risk Factor Surveillance System cross‐sectional survey	29
Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors	28
COVID‐19 outcomes in hospitalized patients with active cancer: Experiences from a major New York City health care system	28
Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group	28
The effect of Medicaid expansion among adults from low‐income communities on stage at diagnosis in those with screening‐amenable cancers	28
Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single‐center, real‐life experience	28
Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study	28
A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability	28
Fear of cancer recurrence and disease progression in long‐term prostate cancer survivors after radical prostatectomy: A longitudinal study	28
Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies	28
Ultrasensitive detection of tumor‐specific mutations in saliva of patients with oral cavity squamous cell carcinoma	27
Metabolic imaging with hyperpolarized 13C pyruvate magnetic resonance imaging in patients with renal tumors—Initial experience	27
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients	27
Quality of life among survivors of adolescent and young adult cancer in Canada: A Young Adults With Cancer in Their Prime (YACPRIME) study	27
The mutational landscape of early‐ and typical‐onset oral tongue squamous cell carcinoma	27
Chronic comorbid conditions among adult cancer survivors in the United States: Results from the National Health Interview Survey, 2002‐2018	27
A Coala‐T‐Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment	27
The central role of provider training in implementing resource‐stratified guidelines for palliative care in low‐income and middle‐income countries: Lessons from the Jamaica Cancer Care and Research In	26
Access denied: The relationship between patient insurance status and access to high‐volume hospitals	26
Cancer‐related mortality among people with intellectual disabilities: A nationwide population‐based cohort study	26
Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis	26
A system for classifying cancers diagnosed in adolescents and young adults	26
SARC‐F for screening of sarcopenia among older adults with cancer	26
Recommendations for the surveillance of education and employment outcomes in survivors of childhood, adolescent, and young adult cancer: A report from the International Late Effects of Childhood Cance	26
Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma	26
Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3‐arm randomized trial	26
The dual pandemic of COVID‐19 and systemic inequities in US Latino communities	26
Financial toxicity, mental health, and gynecologic cancer treatment: The effect of the COVID‐19 pandemic among low‐income women in New York City	26

Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975‐2016	25
NCCN resource‐stratified and harmonized guidelines: A paradigm for optimizing global cancer care	25
Quality measures for end‐of‐life care for children with cancer: A modified Delphi approach	25
Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T‐cell acute lymphoblastic leukemia and lymphoma	25
Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30‐year SIOP‐RTSG experience	25
Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy‐naive men: A prospective evaluation of the PLUM cohort	25
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study	25
Cause of death during prostate cancer survivorship: A contemporary, US population–based analysis	25
Post‐transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA‐identical sibling donors: A retrosp	25
Have incidence rates of liver cancer peaked in the United States?	25
Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non–small cell lung cancer brain metastases	25
Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lympho	24
Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case‐series analysis within the Italian Rare Cancer Network	24
Use of high‐resolution full‐field optical coherence tomography and dynamic cell imaging for rapid intraoperative diagnosis during breast cancer surgery	24
Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors	24
MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor–mutant lung cancers	24
Congruence of patient‐ and clinician‐reported toxicity in women receiving chemotherapy for early breast cancer	24
Defining disease modification in myelofibrosis in the era of targeted therapy	24
Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire	24
Regulatory T cells: Their role in triple‐negative breast cancer progression and metastasis	24
A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer	24
Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration	24
Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes	24
Impact of pathologic lymph node‐positive renal cell carcinoma on survival in patients without metastasis: Evidence in support of expanding the definition of stage IV kidney cancer	23
Prevalence of cannabis use among individuals with a history of cancer in the United States	23
Germline and somatic DNA repair gene alterations in prostate cancer	23
Posttraumatic stress disorder and breast cancer: Risk factors and the role of inflammation and endocrine function	23
Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis	23
Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer	23
Blood‐based biomarkers of human papillomavirus–associated cancers: A systematic review and meta‐analysis	23
Impact of cancer on school, work, and financial independence among adolescents and young adults	23
Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials	23
Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors	23
Clinical outcomes of carbon‐ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma	23
Patterns and predictors of cancer‐related fatigue in ovarian and endometrial cancers: 1‐year longitudinal study	23
Long‐term causes of death among pediatric patients with cancer	23
Financial hardship in Chinese cancer survivors	22
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920	22
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01	22
Treatment patterns and survival in patients with early‐onset pancreatic cancer	22
Curability of patients with lymph node metastases from extremity soft‐tissue sarcoma	22
Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base	22
Association of malnutrition with geriatric assessment impairments and health‐related quality of life among older adults with gastrointestinal malignancies	22
Biomarker‐driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum‐based chemotherapy	22
Clinical and organizational risk factors for mortality during deterioration events among pediatric oncology patients in Latin America: A multicenter prospective cohort	22
Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single‐arm, prospective phase 2 study	22
Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status	22
Association of statin use with clinical outcomes in patients with triple‐negative breast cancer	22
Association of area‐level socioeconomic status and non–small cell lung cancer stage by race/ethnicity and health care–level factors: Analysis of the National Cancer Database	22
Association of GSTM1 null variant with anthracycline‐related cardiomyopathy after childhood cancer—A Children's Oncology Group ALTE03N1 report	22
Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial	22
11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood	21
A lay navigator‐led, early palliative care intervention for African American and rural family caregivers of individuals with advanced cancer (Project Cornerstone): Results of a pilot randomized trial	21
Validation of the 7‐item Functional Assessment of Cancer Therapy‐General (FACT‐G7) as a short measure of quality of life in patients with advanced cancer	21
Racial and ethnic disparities in pediatric cancer incidence among children and young adults in the United States by single year of age	21
Impact of optimizing diagnostic workup and reducing the time to treatment in head and neck cancer	21
Performance of the IBIS/Tyrer‐Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative	21
The efficacy and mechanisms of a guided self‐help intervention based on mindfulness in patients with breast cancer: A randomized controlled trial	21
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer	21
The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort	21
Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study	21
BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and eff	21
Large reduction in opioid prescribing by a multipronged behavioral intervention after major urologic surgery	21
Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG	21
Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the	21
The 3 Bs of cancer care amid the COVID‐19 pandemic crisis: “Be safe, be smart, be kind”—A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer	21
Racial disparities in mortality for patients with prostate cancer after radical prostatectomy	21
Rural‐urban and racial/ethnic trends and disparities in early‐onset and average‐onset colorectal cancer	21
Outcomes after progression of disease with anti–PD‐1/PD‐L1 therapy for patients with advanced melanoma	20
Young adult cancer caregivers' exposure to cancer misinformation on social media	20
Low‐dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment‐free remission in chronic myeloid leukemia patients: Results of a retrospective study	20
Chronic pain severity, impact, and opioid use among patients with cancer: An analysis of biopsychosocial factors using the CHOIR learning health care system	20
Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab	20
Health system strengthening: Integration of breast cancer care for improved outcomes	20
Barriers to the early integration of palliative care in pediatric oncology in 11 Eurasian countries	20
Outcome analysis of stage I epithelial‐predominant favorable‐histology Wilms tumors: A report from Children's Oncology Group study AREN03B2	20
Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors	20
A novel combined resilience and advance care planning intervention for adolescents and young adults with advanced cancer: A feasibility and acceptability cohort study	20
Clinical trial design: Past, present, and future in the context of big data and precision medicine	20
Lung cancer screening use and implications of varying eligibility criteria by race and ethnicity: 2019 Behavioral Risk Factor Surveillance System data	20
Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey	20
Geographic access to lung cancer screening among eligible adults living in rural and urban environments in the United States	20
Spectrum of PALB2 germline mutations and characteristics of PALB2‐related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next‐generation s	20
Patient and diagnostic intervals of survivors of sarcoma: Results from the SURVSARC study	19
Impact of the COVID‐19 pandemic on telehealth research in cancer prevention and care: A call to sustain telehealth advances	19
Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findings	19
Cancer‐related impairments and functional limitations among long‐term cancer survivors: Gaps and opportunities for clinical practice	19
Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer	19
Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era	19
SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma	19
Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group	19
Social needs and health‐related quality of life among African American cancer survivors: Results from the Detroit Research on Cancer Survivors study	19
Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients	19
Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma	19
Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate‐risk and high‐risk head and neck squamous cell carcinoma	19